VEGFA and neoplasm: Brivanib is the first-in-class FGF/VEGF inhibitor currently in late-stage clinical trials, blocking VEGF receptors 1-3 and FGF receptors 1-2 against angiogenic activity and inhibiting FGF-dependent tumor growth 32.